NEW YORK, May 26, 2026, 07:02 EDT
Elutia Inc. stock hovered around $1.15 to $1.16 in quiet premarket U.S. trade on Tuesday after the holiday break. ELUT last traded at $1.15 on 11 shares in premarket, down 0.86%, according to Investing.com. StockAnalysis had the stock at $1.16 at the May 22 close, giving the medical-device maker a market cap near $51.3 million.
The timing is key. Nasdaq’s normal stock session is 9:30 a.m. to 4:00 p.m. Eastern, and premarket runs 4:00 a.m. to 9:30 a.m. U.S. markets shut on Monday, May 25, for Memorial Day. For microcap names, those early prints before the bell often signal more about liquidity than sentiment.
Elutia’s news site had its most recent post as the May 18 inducement-award grant. The investor filings page listed the last SEC filing as the May 15 Form 10-Q. So traders are still watching last week’s disclosures: a Q1 update, a regulatory timeline, and two possible asset sales.
Elutia: Stock option grant gives marker for equity value
Elutia’s May 18 release wasn’t about clinical or sales news. The company disclosed it gave a new employee 48,000 non-qualified stock options as per Nasdaq Listing Rule 5635(c)(4), setting the exercise price at $1.05—matching the shares’ close on May 13. The options are a small grant, but that strike price offers investors a recent board-level marker for where Elutia’s equity stands.
Elutia’s fuller update came four days earlier. The company reported first-quarter net sales up 6% to $3.1 million. Gross margin increased to 57.9% from 46.8%. Cash and escrowed funds totaled $36.5 million at March 31. CEO Randy Mills said surgeon feedback confirmed “the size and severity of the need” for NXT-41x, the firm’s planned antibiotic-eluting biomatrix. Elutia Inc.
Biomatrix is a tissue scaffold used for repair or reconstruction. Elutia’s annual report says NXT-41 and NXT-41x are built as next-generation biologic scaffolds that provide local antibiotic delivery. SimpliDerm competes with other acellular dermal matrix offerings like AbbVie’s AlloDerm, MTF Biologics’ FlexHD and Stryker’s DermACELL. Acellular dermal matrix refers to processed tissue with the cells removed, used as a mesh in soft-tissue surgery.
Elutia execs said possible divestitures fit with its current strategy. On the Q1 call, Chief Financial Officer Matthew Ferguson said the company’s cash gives it “resources necessary to support” key milestones. Responding to Lake Street Capital Markets’ Frank Takkinen on when a SimpliDerm sale might close, Mills said: “But until it’s done, it’s not done.” The Motley Fool
Stock-index futures edged up ahead of the U.S. open. Nasdaq 100 futures gained 0.77% at 4:50 a.m. ET Tuesday, according to Reuters, as traders set aside worries over Middle East tensions. “Investors still appear willing to buy dips,” Capital.com’s Daniela Hathorn said. Reuters
Elutia’s trade isn’t one-way. The company’s latest quarterly filing spells out risks over getting FDA marketing authorizations, raising money, hitting profitability, litigation, staying on Nasdaq, and competition. It posted a first-quarter net loss of $7.5 million, or 17 cents a share. Delays to NXT-41 or NXT-41x, or if the asset sale falls short, could shift focus back to cash burn away from the product story.
The focus next week shifts from waiting for a set event to watching for signals. Traders will look at post-holiday volume, news on the SimpliDerm or Cardiovascular fronts, and whether buyers show up in smaller healthcare names. These could be what tells if ELUT stays above the $1 mark or if trading swings back to betting on the FDA timeline after earnings.
